Third Rock Ventures Ii, L.P. Jounce Therapeutics, Inc. (JNCE) insider trading activity

Third Rock Ventures Ii, L.P. is > 10% Shareholder of Jounce Therapeutics, Inc.. Currently has a direct ownership of 2.7 Million shares of JNCE, which is worth approximately $0. The most recent transaction as insider was on Sep 15, 2021, when has been sold 1,750,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.7M

0% 3M change

0% 12M change

Total Value Held $0

Third Rock Ventures II, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 15 2021	SELL Other acquisition or disposition	-	1,750,000 Reduced 39.35%	2,697,829 Common Stock
Jun 10 2021	SELL Other acquisition or disposition	-	1,500,000 Reduced 25.22%	4,447,829 Common Stock
May 25 2021	SELL Open market or private sale	$4,420,160 $8.0 p/Share	552,520 Reduced 8.5%	5,947,829 Common Stock
Mar 11 2021	SELL Other acquisition or disposition	-	1,250,000 Reduced 16.13%	6,500,349 Common Stock
Mar 01 2021	SELL Open market or private sale	$17,037,500 $11.75 p/Share	1,450,000 Reduced 15.76%	7,750,349 Common Stock
Nov 19 2020	SELL Open market or private sale	$105,000 $7.0 p/Share	15,000 Reduced 0.16%	9,200,349 Common Stock
Nov 17 2020	SELL Open market or private sale	$108,750 $7.25 p/Share	15,000 Reduced 0.16%	9,215,349 Common Stock
Nov 11 2020	SELL Other acquisition or disposition	-	1,000,000 Reduced 9.77%	9,230,349 Common Stock

Also insider at

MYOK

MyoKardia Inc

> 10% Shareholder

ALNA

Allena Pharmaceuticals, Inc. Healthcare

> 10% Shareholder

RVMD

Revolution Medicines, Inc. Healthcare

> 10% Shareholder

TRV